NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Michael Makris: NovoNordisk Has Applied to the FDA for Approval of Mim8
Michael Makris/eahad.org
Sep 29, 2025, 21:11

Michael Makris: NovoNordisk Has Applied to the FDA for Approval of Mim8

Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared on LinkedIn:

‘‘NovoNordisk has applied to the FDA for approval of Mim8, a bispecific antibody which will be a direct competitor to emicizumab (Hemlibra).

The data we have seen presented at scientific meetings and published are strong, and suggest that approval is likely to be given.”

Read the full article here.

Article: Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors

Michael Makris: NovoNordisk Has Applied to the FDA for Approval of Mim8

Stay updated on the emerging in the field of Hemophilia with Hemostasis Today.

bleeding disorders Emicizumab FDA Headlines Health Hematology Hemlibr Hemophilia Hemostasis Hemostasis Today Medicine Michael Makris Mim8 NovoNordisk
NewsFeed